Strides Pharma Science · NSE: STAR · BSE: 532531
Q2 FY19 results · Jul–Sep 2018
Strides Pharma Science reported revenue from operations of ₹732.63 crore and net loss of ₹8.70 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 732.63 | — | — | 663.46 | +10.4% |
| Other income | 7.73 | — | — | 10.64 | −27.3% |
| Total income | 740.36 | — | — | 674.10 | +9.8% |
| Profit before share of associates & JVs and tax | 6.97 | — | — | (0.51) | Turned profit |
| Share of profit/(loss) of associates & JVs | (12.30) | — | (7.91) | ||
| Net profit for the period | (8.70) | — | — | (4.16) | Loss widened |
| Attributable to shareholders of the company | (12.01) | — | — | (5.91) | Loss widened |
| EPS, basic (₹) | (1.34) | — | — | (0.66) | Loss widened |
| Net margin (%) | -1.2 | — | -0.6 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 338.43 | — | — | 349.77 | −3.2% |
| Other income | 20.36 | — | — | 15.77 | +29.1% |
| Total income | 358.79 | — | — | 365.54 | −1.8% |
| Profit before tax | (11.59) | — | — | 11.92 | Turned loss |
| Net profit for the period | (14.30) | — | — | 10.54 | Turned loss |
| EPS, basic (₹) | (1.60) | — | — | 1.18 | Turned loss |
| Net margin (%) | -4.2 | — | 3.0 |
Consolidated
- Filed with BSE
- 31 Oct 2018, 17:58 IST
- Board meeting
- 31 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Oct 2018, 17:58 IST
- Board meeting
- 31 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE